Kronos Bio Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Kronos Bio, Inc. (Nasdaq: KRON) announced participation in two upcoming investor conferences. On Dec. 2, 2020, at 2:15 p.m. ET, management will engage in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference. Additionally, on Dec. 3, 2020, meetings will take place at the Piper Sandler 32nd Annual Virtual Healthcare Conference, featuring a pre-recorded fireside chat available from 10 a.m. ET. The events will be accessible via the company’s website, with replays available for one month.

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in the following investor conferences:

• A virtual fireside chat at the Evercore ISI 3^rd Annual HealthCONx Conference on Wednesday, Dec. 2, 2020, at 2:15 p.m. ET; and
• Meetings at the Piper Sandler 32^nd Annual Virtual Healthcare Conference on Thursday, Dec. 3, 2020, with a pre-recorded fireside chat available today at 10 a.m. ET.

The fireside chats will be available from the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcast will be archived and available for one month following the event.

About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Contact:
Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-525-6605
media@kronosbio.com

FAQ

What investor conferences is Kronos Bio participating in December 2020?

Kronos Bio will participate in the Evercore ISI 3rd Annual HealthCONx Conference on Dec. 2, 2020, and the Piper Sandler 32nd Annual Virtual Healthcare Conference on Dec. 3, 2020.

When can I watch Kronos Bio's fireside chat at the Evercore ISI conference?

The fireside chat at the Evercore ISI conference will take place on Dec. 2, 2020, at 2:15 p.m. ET.

Where can I find the recordings of Kronos Bio's investor events?

Recordings of Kronos Bio's investor events will be available in the Investors & Media section of their website for one month after the events.

What is the focus of Kronos Bio's research and development?

Kronos Bio focuses on discovering and developing therapies for cancer, targeting dysregulated transcription factors and associated regulatory networks.

What is Kronos Bio's lead investigational therapy?

Kronos Bio's lead investigational therapy is entospletinib, targeting spleen tyrosine kinase (SYK) for NPM1-mutated acute myeloid leukemia (AML).